MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in…
MaaT PharmaNovember 6, 2023
MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed…
MaaT PharmaOctober 31, 2023
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial…
MaaT PharmaOctober 26, 2023
MaaT Pharma: Increase in Resources Allocated to the Liquidity Contract With the Brokerage Firm Kepler…
MaaT PharmaOctober 9, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
MaaT PharmaOctober 6, 2023
MaaT Pharma Announces Poster Presentations at the 38th Annual Meeting of the Society for Immunotherapy…
MaaT PharmaSeptember 27, 2023
MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update The ARES…
MaaT PharmaSeptember 26, 2023
